论文部分内容阅读
目的探讨肾癌相关蛋白G250mRNA在肾细胞癌(RCC)中的表达及其临床意义。方法采用RTPCR方法检测7例正常肾组织和33例RCC组织中G250mRNA的表达。33例RCC中透明细胞癌28例,非透明细胞癌5例;T18例、T213例、T312例;G111例、G215例、G37例。结果33例RCC组织中G250mRNA表达阳性28例(84.8%),7例正常组织G250表达均为阴性,2组间差异有统计学意义(P<0.01)。肾透明细胞癌组织G250mRNA表达率高于非透明细胞癌[96.4%(27/28)和20.0%(1/5),P<0.05]。T1、T2、T3RCCG250mRNA表达量分别为0.32±0.21、0.41±0.16、0.38±0.14,表达量与临床分期无相关性(P>0.05)。G1、G2、G3RCCG250mRNA表达量分别为0.48±0.32、0.23±0.16、0.11±0.11,表达量与病理分级呈负相关(P<0.05)。结论G250mRNA表达与RCC恶性程度有相关性,有望成为RCC诊断及预后判断的指标。
Objective To investigate the expression of renal cell carcinoma-related protein G250 mRNA in renal cell carcinoma (RCC) and its clinical significance. Methods RTPCR was used to detect the expression of G250mRNA in 7 normal renal tissues and 33 RCC tissues. Among the 33 RCC cases, there were 28 cases of clear cell carcinoma and 5 cases of non-clear cell carcinoma; T18 cases, T213 cases and T312 cases; G111 cases, G215 cases and G37 cases. Results The expression of G250 mRNA in 33 cases of RCC was positive in 28 cases (84.8%), while in 7 cases of normal tissue, the expression of G250 was negative. The difference between the two groups was statistically significant (P <0.01). The positive rate of G250mRNA in renal clear cell carcinoma was higher than that in non-clear cell carcinoma [96.4% (27/28) and 20.0% (1/5), P <0.05]. The expression levels of T1, T2 and T3RCCG250 mRNA were 0.32 ± 0.21, 0.41 ± 0.16 and 0.38 ± 0.14, respectively. There was no correlation between the expression level and clinical stage (P> 0.05). The expressions of G1, G2 and G3RCCG250 mRNA were 0.48 ± 0.32, 0.23 ± 0.16 and 0.11 ± 0.11, respectively. There was a negative correlation between the expression level and pathological grade (P <0.05). Conclusion The expression of G250mRNA is correlated with the degree of malignancy of RCC, which is expected to be an index of diagnosis and prognosis of RCC.